Page 85 - Read Online

Page 22 of 22 García-Pardo et al. J Cancer Metastasis Treat 2021;7:62 https://dx.doi.org/10.20517/2394-4722.2021.103

148. Molica S, Montillo M, Ribatti D, et al. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and
alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia. Haematologica 2007;92:1367-74. PubMed
149. López-Guerra M, Xargay-Torrent S, Rosich L, et al. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes
migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia 2015;29:96-106. DOI PubMed
150. Maffei R, Fiorcari S, Vaisitti T, et al. Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and
microenvironmental survival signals in chronic lymphocytic leukemia. Oncotarget 2017;8:90013-27. DOI PubMed PMC
151. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis
factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80. DOI PubMed PMC
152. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A
1994;91:4082-5. DOI PubMed PMC
153. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as
initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005;106:3348-52. DOI PubMed
154. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
DOI PubMed PMC
155. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic
lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-9. DOI PubMed
156. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory
chronic lymphocytic leukemia. Blood 2008;111:5291-7. DOI PubMed PMC
157. Maffei R, Fiorcari S, Bulgarelli J, et al. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected
by lenalidomide treatment in chronic lymphocytic leukemia. Exp Hematol 2014;42:126-36.e1. DOI PubMed
158. Aue G, Nelson Lozier J, Tian X, et al. Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in
chronic lymphocytic leukemia. Am J Hematol 2011;86:835-40. DOI PubMed PMC
159. Egle A, Steurer M, Melchardt T, et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by
lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT
phase I/II study. Ann Hematol 2018;97:1825-39. DOI PubMed PMC
160. Mauro FR, Carella AM, Molica S, et al. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic
lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leuk Lymphoma 2017;58:1640-7. DOI PubMed
161. Strati P, Takahashi K, Peterson CB, et al. Efficacy and predictors of response of lenalidomide and rituximab in patients with
treatment-naive and relapsed CLL. Blood Adv 2019;3:1533-9. DOI PubMed PMC
162. Ossenkoppele GJ, Stussi G, Maertens J, et al. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a
randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for
Clinical Cancer Research (SAKK). Blood 2012;120:4706-11. DOI PubMed
163. Paesler J, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA. Targeting the vascular endothelial growth factor in hematologic malignancies.
Eur J Haematol 2012;89:373-84. DOI PubMed
164. Bogusz J, Majchrzak A, Mędra A, Cebula-Obrzut B, Robak T, Smolewski P. Mechanisms of action of the anti-VEGF monoclonal
antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw (Online) 2013;67:107-18. DOI PubMed
165. Shanafelt T, Zent C, Byrd J, et al. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.
Leuk Lymphoma 2010;51:2222-9. DOI PubMed PMC
166. Kay NE, Strati P, LaPlant BR, et al. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in
previously untreated patients with chronic lymphocytic leukemia. Oncotarget 2016;7:78269-80. DOI PubMed PMC
167. Paesler J, Gehrke I, Gandhirajan RK, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and
pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res 2010;16:3390-8.
DOI PubMed
168. Cornwall S, Cull G, Joske D, Ghassemifar R. Green tea polyphenol "epigallocatechin-3-gallate", differentially induces apoptosis in
CLL B-and T-Cells but not in healthy B-and T-Cells in a dose dependant manner. Leuk Res 2016;51:56-61. DOI PubMed
169. Huber S, Oelsner M, Decker T, et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation
of Mcl-1. Leukemia 2011;25:838-47. DOI PubMed
170. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ. Chronic lymphocytic leukemia cells receive RAF-dependent
survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011;117:882-9. DOI PubMed PMC
171. Dwojak M, Bobrowicz M, Bil J, et al. Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of
complement regulatory proteins. Blood Cancer J 2015;5:e300. DOI PubMed PMC